Lars Hertzog
Ophthalmology · Long Beach, CANPI 1629164454
Payments from drug & device makers
Across 81 payments — averaging $62.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$3K
- Alcon$406
- AbbVie$280
- Sun Pharmaceutical Industries Inc.$275
- Bausch & Lomb, A Division Of Bausch Health US, LLC$207
- Novartis$118
- plus $649 from 15 others
What the payments were for
- Speaking & faculty fees$3,00059%
- Food & beverage$2,04840%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 5 | $3,132 |
| Alcon | 13 | $406 |
| AbbVie(2 entities) | 9 | $280 |
| Sun Pharmaceutical Industries Inc. | 11 | $275 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $207 |
| Novartis | 6 | $118 |
| Dompe US, Inc. | 4 | $94 |
| Tarsus Pharmaceuticals, Inc. | 3 | $76 |
| Amgen | 4 | $73 |
| Coopervision Inc. | 2 | $67 |
| Ocular Therapeutix, Inc. | 3 | $66 |
| Bausch & Lomb Americas Inc. | 3 | $61 |
| Oyster Point Pharma, Inc. | 2 | $42 |
| Sight Sciences, Inc. | 2 | $30 |
| Aerie Pharmaceuticals, Inc. | 2 | $29 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Optos, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $17 |
| Biotissue Holdings Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,068 in reported general payments places this provider in the 70th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 59 | $68,344 |
| LumiganBimatoprost | 56 | $30,192 |
| Cyclosporine | 36 | $25,890 |
| RocklatanNetarsudil Mesylat/Latanoprost | 28 | $22,138 |
| Prednisolone Acetate | 450 | $19,061 |
| Latanoprost | 1,075 | $13,601 |
| VyzultaLatanoprostene Bunod | 20 | $8,892 |
| Travoprost | 48 | $7,666 |
| Timolol Maleate | 298 | $6,988 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $6,545 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 16 | $6,434 |
| MoxifloxacinMoxifloxacin Hcl | 293 | $4,926 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 173 | $4,003 |
| Brinzolamide | 29 | $3,949 |
| ZioptanTafluprost/Pf | 16 | $3,870 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $280 | $105,081134 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $29 | $22,13828 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $61 | $8,89220 claims |
| AlconSimbrinza | $406 | $6,43416 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $207 | $1,77715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Long Beach
- Julie GasperiniLong Beach$814K
- Carl HartmanLong Beach$716K
- Dan TranLong Beach$649K
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.